First line chemo-free therapy with the BRAF inhibitor vemurafenib combined with obinutuzumab is effective in patients with HCL Meeting Abstract
| Authors: | Park, J. H.; Shukla, M.; Salcedo, J. M.; Vemuri, S.; Kinoshita, J. C.; Smith, M. D.; Winer, E. S.; Abdel-Wahab, O.; Tallman, M. S. |
| Abstract Title: | First line chemo-free therapy with the BRAF inhibitor vemurafenib combined with obinutuzumab is effective in patients with HCL |
| Meeting Title: | 61st Annual Meeting and Exposition of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 134 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Dec 7-10 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2019-11-13 |
| Language: | English |
| ACCESSION: | WOS:000577164602021 |
| DOI: | 10.1182/blood-2019-124478 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 3998 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
